Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

• Published in: Biomedicine & pharmacotherapy Vol. 145; p. 112243
• Main Authors: Raghavan, Kadalraja, Dedeepiya, Vidyasagar Devaprasad, Suryaprakash, Vaddi, Rao, Kosagi-Sharaf, Ikewaki, Nobunao, Sonoda, Tohru, Levy, Gary A., Iwasaki, Masaru, Senthilkumar, Rajappa, Preethy, Senthilkumar, Abraham, Samuel JK
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2022; The Authors. Published by Elsevier Masson SAS
• Subjects: Adjunct treatment; Aureobasidium; Beta glucans; beta-Glucans - administration & dosage; Biomarkers - blood; Coagulopathy; Complementary Therapies - methods; COVID-19; COVID-19 - blood; COVID-19 - diagnosis; COVID-19 Drug Treatment; Cytokine Release Syndrome - blood; Cytokine Release Syndrome - etiology; Cytokine Release Syndrome - prevention & control; Cytokine storm; D-dimer; Dietary Supplements; Female; Fibrin Fibrinogen Degradation Products - analysis; Humans; IL-6; Immuno-modulation; Immunologic Factors - administration & dosage; Interleukin-6 - analysis; Male; Middle Aged; Pilot Projects; SARS-CoV-2; Treatment Outcome; COVID-19; Adjunct treatment; D-dimer; Immuno-modulation; Cytokine storm; Beta glucans; IL-6; Coagulopathy

In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients. A total of 24 RT-PCR positive COVID-19 patients were recruite...